Journal of Neurology, Neurosurgery & Psychiatry
Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab
Myasthenia gravis (MG) is a disease of the neuromuscular junction, usually caused by an autoimmune process associated with antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Rituximab (RTX), a monoclonal antibody targeting CD20, has emerged as a potential treatment in the management of MG, in particular for MuSK positive patients.1 2 Most (80%) patients received 375 mg/m2 of RTX per week for 4 weeks, with lower doses being infrequently reported.
We previously reported on our experience with low-dose RTX in the treatment of MG3 and now report our long-term experience from an enlarged cohort.
We identified retrospectively all patients with MG treated with RTX between May 2006 and July 2017 in South East Queensland, Australia. Cases were identified via review of pharmacy and hospital records as well as by direct contact with the treating neurologists.
Source: Journal of Neurology, Neurosurgery & Psychiatry